Catalyst

Slingshot members are tracking this event:

Gilead (GILD) Announces Top-Line Phase 2 Data for GS-4997 in Nonalcoholic Steatohepatitis (NASH)

Source Link:
http://www.gilead.com/news/press-releases/2016/10/gilead-announces-topline-phase-2-results-for-gs4997-selonsertib-in-nonalcoholic-steatohepatitis-nash-pulmonary-arterial-hypertension-pah-and-diabetic-kidney-disease-dkd

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GILD
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Oct 20, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Top-line, Phase 2, Gs-4997, Selonsertib, Nonalcoholic Steatohepatitis, Nash
About Us
Media Center
Connect with Us
© 2025 Slingshot Insights. All rights reserved.